Beta Lactam and Beta Lactamase Inhibitors Market to grow by USD 8.4 Billion (2025-2029), driven by novel drug development, AI-powered market evolution - Technavio
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global beta lactam and beta lactamase inhibitors market size is estimated to grow by USD 8.4 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 4.7% during the forecast period. Rising focus on novel drug development is driving market growth, with a trend towards technological advancements in antibiotic discovery. However, emergence of carbapenem-resistant enterobacteriaceae (cre) poses a challenge. Key market players include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sandoz Group AG, Sanofi SA, Spero Therapeutics Inc., Taj Pharmaceutical Ltd., and Zeelab Laboratories Ltd..
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF
Beta Lactam And Beta Lactamase Inhibitors Market Scope
Report Coverage
Details
Base year 2024
Historic period
2019 - 2023
Forecast period
2025-2029
Growth momentum & CAGR Accelerate at a CAGR of 4.7%
Market growth 2025-2029
USD 8400.9 million
Market structure
Fragmented
YoY growth 2022-2023 (%) 4.4
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution North America at 39%
Key countries
US, China, Germany, India, and UK
Key companies profiled Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Inc., F. Hoffmann La Roche Ltd.,
GlaxoSmithKline Plc, Lupin Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sandoz Group AG, Sanofi
SA, Spero Therapeutics Inc., Taj Pharmaceutical Ltd., and Zeelab Laboratories Ltd.
Market Driver
The Beta Lactam and Beta Lactamase Inhibitors market is witnessing significant growth due to the increasing prevalence of infectious diseases caused by antibiotic-resistant microorganisms. Penicillin, Cephalosporin, Carbapenem, Monobactam are key antibacterial agents in this market. Combination therapies with Beta Lactamase Inhibitors are trending, especially in Urinary Tract Infections, Respiratory Infections, and Skin Infections. New molecules and oral formulations are in clinical trials to cater to the elderly population and chronic diseases. The drug class is administered through various routes, including Intravenous and oral, for conditions like Nosocomial Pneumonia, Hospital-acquired pneumonia, Ventilator-associated pneumonia, and Blood Stream Infections. Amalgamation traits of Beta Lactam and Beta Lactamase Inhibitors offer effective solutions to combat antibiotic resistance. Creative Diagnostics is a leading supplier of Beta Lactamase Inhibitors for research and diagnostic applications.
Advancements in antibiotic discovery employ high-throughput screening (HTS) techniques to identify potential beta lactam antibiotics and inhibitors. HTS allows for the rapid testing of large chemical compound libraries, accelerating the discovery process and leading to the identification of novel, more effective beta lactamase inhibitors. Computational modeling, including molecular docking and virtual screening, further enhances this process by predicting binding interactions between beta-lactam antibiotics, inhibitors, and bacterial targets, ultimately contributing to the development of new antibiotics to combat antimicrobial resistance and infectious diseases.
Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!
Market Challenges
-- The Beta Lactam and Beta Lactamase Inhibitors market encompasses
antibacterial agents used to combat various microorganisms causing
Urinary Tract Infections, Respiratory Infections, Skin Infections,
Nosocomial Pneumonia, and Blood Stream Infections. Penicillin,
Cephalosporin, Carbapenem, and Monobactam are key drug classes. However,
antibiotic resistance poses a significant challenge. Creating new
molecules and combination therapies, such as Cephalosporin with Beta
Lactamase Inhibitors, is crucial. Route of administration varies from
Intravenous to Oral. The prevalence of infectious diseases, particularly
in the elderly population, increases the market demand. Amalgamating
traits of both antibiotics and inhibitors can lead to effective
treatments for chronic diseases and complex infections like
Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, and more.
Clinical trials are ongoing to ensure safety and efficacy.
-- Carbapenem-resistant Enterobacteriaceae (CRE) strains pose significant
challenges for healthcare providers due to their resistance to
carbapenem antibiotics, which are commonly used for treating serious
bacterial infections. The emergence of CREs limits effective treatment
options, leading to increased morbidity and mortality rates for
patients. Infections caused by CREs are often associated with prolonged
hospitalization and higher healthcare costs. These bacteria are commonly
found in healthcare settings, including hospitals, long-term care
facilities, and intensive care units, making infection control efforts
crucial. Nosocomial transmission of CREs among patients can lead to
outbreaks and healthcare-associated infections, further complicating
treatment and increasing the risk of dissemination within healthcare
facilities. Effective strategies for managing CRE infections include the
use of beta-lactam/beta-lactamase inhibitor combinations and other
alternative antibiotics.
Discover how AI is revolutionizing market trends- Get your access now!
Segment Overview
This beta lactam and beta lactamase inhibitors market report extensively covers market segmentation by
1. Route Of Administration
-- 1.1 Oral
-- 1.2 Intravenous
-- 1.3 Others
2. Drug Class
-- 2.1 Cephalosporins
-- 2.2 Penicillins
-- 2.3 Carbapenem
-- 2.4 Monobactum
-- 2.5 Combination
3. Geography
-- 3.1 North America
-- 3.2 Europe
-- 3.3 Asia
-- 3.4 Rest of World (ROW)
1.1 Oral-
Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics
Research Analysis
The Beta Lactam and Beta Lactamase Inhibitors market refers to a class of antibacterial agents used to treat various bacterial infections. These agents work by inhibiting the action of beta-lactamases, enzymes produced by microorganisms that can break down antibiotics like Penicillin, Cephalosporin, Carbapenem, Monobactam, and others. New molecules and combination therapies are being developed to combat the growing resistance to beta-lactam antibiotics. Clinical trials are ongoing to evaluate the safety and efficacy of these new drugs, particularly in the treatment of chronic diseases and in the elderly population. Beta-lactam and beta-lactamase inhibitors are available in various forms, including oral preparations, and are used to treat a wide range of bacterial infections.
Market Research Overview
Beta lactam and beta lactamase inhibitors are a class of antibacterial agents used to treat various bacterial infections. These agents work by inhibiting the action of beta-lactamases, enzymes produced by microorganisms that can break down antibiotics like penicillin, cephalosporin, carbapenem, monobactam, and others. The use of beta lactam and beta lactamase inhibitors is essential in the treatment of urinary tract infections, respiratory infections, skin infections, nosocomial pneumonia, bloodstream infections, hospital-acquired pneumonia, and ventilator-associated pneumonia. With the increasing prevalence of infectious diseases and the emergence of antibiotic resistance, the development of new molecules and combination therapies is a priority. The drug class is available in various routes of administration, including intravenous and oral forms. The elderly population and those with chronic diseases are particularly susceptible to bacterial infections and benefit from the use of these agents. The amalgamation of traits from different beta lactam antibiotics in combination therapies offers improved efficacy and reduced risk of resistance. Creative Diagnostics provides comprehensive solutions for beta lactam and beta lactamase inhibitors, including assay kits, antibodies, and services, to support research and development in this field.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
-- Route Of Administration
-- Oral
-- Intravenous
-- Others
-- Drug Class
-- Cephalosporins
-- Penicillins
-- Carbapenem
-- Monobactum
-- Combination
-- Geography
-- North America
-- Europe
-- Asia
-- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/beta-lactam-and-beta-lactamase-inhibitors-market-to-grow-by-usd-8-4-billion-2025-2029-driven-by-novel-drug-development-ai-powered-market-evolution---technavio-302362566.html
SOURCE Technavio
